RTP Mobile Logo
Patterns of Care: Breast Cancer Edition, Issue 1, 2011
Released April 2011

Survey of 100 Practicing Medical Oncologists on Clinical Scenarios and Patient Cases Presented by Contributing Faculty Members Drs Eric P Winer and Joseph A Sparano. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    It is important for medical oncologists, hematologists and fellows to be aware of similarities and differences between their patterns of cancer care and those of other community practitioners. Additionally, the recognition that heterogeneity exists within the treating oncology community underscores the existence of clinical situations for which the research evidence to support a single definitive approach may be suboptimal.

    This program focuses on the self-described practice patterns of randomly selected community medical oncologists and hematologists in a variety of key clinical scenarios in breast cancer. Also included are clinical investigator commentaries describing clinical scenario-related treatment selections and management patterns. This CME program provides medical oncologists, hematologists and hematology-oncology fellows with information on national cancer patterns of care to assist with the development of best-practice clinical management strategies for breast cancer.

    LEARNING OBJECTIVES

    • Compare and contrast management strategies employed by community-based medical oncologists and clinical investigators in the treatment of breast cancer, and use this information to refine or validate practical treatment decision-making.
    • Identify clinical scenarios for which relative agreement and heterogeneity exist in patterns of breast cancer care, and apply these findings to the individualized care of patients.
    • Counsel patients with breast cancer about the benefits and risks of multiple acceptable evidence-based treatment options when they exist.
    • Apply the results of new data with biomarkers and multigene assays to the routine care of patients with breast cancer.
    • Explain to patients how breast cancer molecular subtype influences disease prognosis and selection of appropriate systemic treatment.
    • Recognize the rate at which practice-changing clinical research influences oncologist behavior, and explain how this affects patient access to standard and novel therapeutics.
    • Recall the design and eligibility criteria for ongoing breast cancer clinical trials, and consent or refer appropriate patients for study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    COMMERCIAL SUPPORT

    This program is supported by educational grants from Genentech BioOncology, Genomic Health Inc and Sanofi-Aventis.

    PHARMACEUTICAL AGENTS DISCUSSED IN THIS PROGRAM

    This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies
    referenced and patient care recommendations.

    CME DISCLOSURES FOR QUOTED FACULTY

    Drs Burstein, Carey, Geyer, Goss, Gralow and Osborne, Prof Untch and Drs Winer and Wolff had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BrufskyConsulting Agreements: Genentech BioOncology, Novartis Pharmaceuticals Corporation; Speakers Bureau: Novartis Pharmaceuticals Corporation, Sanofi-Aventis. Dr CobleighAdvisory Committee: Eisai Inc, Genentech BioOncology, Genomic Health Inc; Paid Research: Genentech BioOncology. Dr EllisAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr GianniAdvisory Committee: Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi-Aventis; Consulting Agreements: Biogen Idec, GlaxoSmithKline, Millennium — The Takeda Oncology Company. Dr GradisharAdvisory Committee: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr KropPaid Research: Genentech BioOncology, Novartis Pharmaceuticals Corporation. Dr MackeyAdvisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems Incorporated, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr MillerAdvisory Committee: Genentech BioOncology, MethylGene Inc, Roche Laboratories Inc; Speakers Bureau: Genentech Bio-Oncology, Roche Laboratories Inc. Dr MussConsulting Agreements: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Pfizer Inc, Roche Laboratories Inc, Sandoz, Wyeth. Dr O’ShaughnessyAdvisory Committee: Genentech BioOncology; Speakers Bureau: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology; Lilly USA LLC, Sanofi-Aventis. Dr PegramAdvisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Sanofi-Aventis; Consulting Agreements: Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Data and Safety Monitoring Board: Wyeth; Paid Research: Genentech BioOncology, Sanofi-Aventis; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis. Dr PerezPaid Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc, Sanofi-Aventis. Dr Piccart-GebhartAdvisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr PressAdvisory Committee: GlaxoSmithKline; Paid Research: Genentech BioOncology, GlaxoSmithKline. Dr RobertAdvisory Committee and Paid Research: Sanofi-Aventis; Consulting Agreement: Novartis Pharmaceuticals Corporation; Speakers Bureau: Roche Laboratories Inc. Prof RobertsonAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals; Consulting Agreement and Stock Ownership: Oncimmune Ltd; Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Oncimmune Ltd; Speakers Bureau: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline. Dr SlamonHonoraria: Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Paid Travel: Genentech BioOncology, Roche Laboratories Inc, Sanofi-Aventis; Stock Ownership: Amgen Inc, Pfizer Inc, Schering-Plough Corporation. Prof SmithAdvisory Committee: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Lecturing: GlaxoSmithKline, Roche Laboratories Inc. Dr SparanoAdvisory Committee: Abraxis Bio-Science Inc, a wholly owned subsidiary of Celgene Corporation, Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, Pfizer Inc; Consulting Agreement: Eisai Inc; Speakers Bureau: BristolMyers Squibb Company, Genentech BioOncology, GlaxoSmithKline. Dr SwainPaid Research: Bristol-Myers Squibb Company, Genentech BioOncology; Paid Travel: Sanofi-Aventis. Dr VahdatConsulting Agreement: Eisai Inc; Paid Research and Speakers Bureau: Bristol-Myers Squibb Company. 

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2011
    Expiration date: April 2012

Acknowledge and close

Listen to audio interviews:
Patterns of Care: Breast Cancer Edition, Issue 1, 2011
Released April 2011

Survey of 100 Practicing Medical Oncologists on Clinical Scenarios and Patient Cases Presented by Contributing Faculty Members Drs Eric P Winer and Joseph A Sparano. (Text and Audio Content)

Read print: